Diabetes Mellitus
Conditions
Keywords
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases, Exendin-4
Brief summary
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus
Detailed description
Primary Objective \- effect of multiple different weekly and monthly doses of HM11260C and liraglutide (Victoza) as active control on gastric emptying Secondary Objectives * evaluate the pharmacodynamic (PD) effects of multiple weekly and monthly doses of HM11260C and liraglutide after a Mixed Meal Tolerance Test * evaluate the islet β-cell function after a graded glucose infusion (GGI) of different doses of HM11260C and liraglutide * evaluate safety and tolerability of different doses of HM11260C and liraglutide * evaluate the pharmacokinetic (PK) effect of multiple weekly and monthly doses of HM11260C
Interventions
Sponsors
Hanmi Pharmaceutical Company Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adults ≥18 to ≤ 70 years of age at the time of the Screening Visit * History of type 2 diabetes * Body mass index (BMI) ≥18 to ≤45 kg/m2 at the Screening Visit * Use of approved methods of contraception * Ability to provide written informed consent
Exclusion criteria
* Type 1 diabetes * Significant acute diabetic proliferative retinopathy or severe neuropathy * Systolic blood pressure \>160 mm Hg and/or diastolic blood pressure \>100 mm Hg at screening * Pregnant or lactating women * Participation in an investigational study within 30 days prior to randomization * History of any major surgery within 6 months prior to Screening * History of any serious adverse reaction or hypersensitivity to any of the product components. * History of renal disease or significantly abnormal kidney function tests at Screening * History of hepatic disease or significantly abnormal liver function tests * History of any active infection within 30 days prior to Randomization * Presence of clinically significant physical, laboratory, or ECG findings at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results * Concurrent conditions that could interfere with safety and/or tolerability measurements per the investigator * Donation or loss of \>500 mL of blood or blood product within 56 days of Randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK profile of acetaminophen | 13 weeks | Cmax, AUC at 13 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glucose metabolism | 13 weeks | Fasting plasma glucose (FPG), Postprandial glucose (PPG), Insulin, C-peptide, HbA1c at 13 weeks |
| Safety and tolerability | 18 weeks | Incidence and severity of adverse events, findings on physical examination, clinical laboratory abnormalities at 18 weeks |
Countries
United States
Contacts
Primary ContactHanmi Clinical
Outcome results
None listed